局部放疗与可测量残留病驱动的免疫治疗用于早期滤泡性淋巴瘤患者(FIL MIRO):一项前瞻性、多中心、2期试验的最终结果
这项前瞻性多中心2期试验在意大利27个中心纳入110例新诊断早期滤泡性淋巴瘤患者,先接受24 Gy受累野放疗12天,放疗后或随访中可测量残留病(MRD)阳性者接受奥法木单抗8次静脉输注(每次1000 mg,每周一次)。放疗后MRD阳性者中奥法木单抗使23/25例(92%,95%CI 74-99)达到MRD阴性,中位随访46.1个月后23例中14例(61%)仍完全缓解且MRD阴性。
要点
- 放疗后仅12/30例(40%)达到MRD阴性,提示局部放疗常不能根除滤泡性淋巴瘤。
- 放疗后MRD阳性者接受奥法木单抗后23/25例(92%,95%CI 74-99)达到MRD阴性。
- 中位随访46.1个月,23例中14例(61%)仍完全缓解且MRD阴性。
核心结论
- 局部放疗常不能根除滤泡性淋巴瘤;MRD驱动的抗CD20单克隆抗体巩固治疗使几乎所有患者达到分子学缓解,并与随时间推移复发发生率降低相关,提示MRD驱动巩固治疗可能具有临床优势。
研究设计与样本
- 前瞻性、多中心、2期试验,在意大利Fondazione Italiana Linfomi(FIL)的27个中心开展。
- 纳入110例新诊断、组织学确诊的滤泡性淋巴瘤成人患者(≥18岁,I或II期,1-IIIa级),其中106例(96%)符合条件并接受受累野放疗。
- 患者先接受24 Gy受累野放疗12天;放疗后或随访中MRD阳性者接受奥法木单抗8次静脉输注(每次1000 mg,每周一次)。
- 主要终点为受累野放疗后MRD阳性且经奥法木单抗治疗后转为MRD阴性的患者比例;入组时外周血或骨髓BCL2::IGH重排阳性者纳入主要终点分析人群。
- 试验注册号EudraCT 2012-001676-11;入组时间为2015年5月2日至2018年6月1日。
主要发现
- 106例接受放疗的患者中,105例(99%)为白人,1例(1%)为黑人;男性50例(47%),女性56例(53%)。
- 105例可评估BCL2::IGH状态的患者中,32例(30%)基线可检测到BCL2::IGH重排。
- 放疗后30例患者中12例(40%)达到MRD阴性,其中3例(25%)MRD阴性持续至少36或42个月。
- 放疗后MRD阳性的可评估患者中,奥法木单抗使23/25例(92%;95%CI 74-99)达到MRD阴性。
- 中位随访46.1个月(IQR 42.8-50.8)后,这23例中14例(61%)仍处于完全缓解且MRD阴性;最常见的3-4级不良事件为输注相关反应,见于4例患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mainstay of treatment for early-stage follicular lymphoma is local radiotherapy, with a possible role for anti-CD20 monoclonal antibody (mAb). We aimed to evaluate the effect of these treatments using a measurable residual disease (MRD)-driven approach. METHODS: This prospective, multicentre, phase 2 trial was conducted at 27 centres of the Fondazione Italiana Linfomi (FIL) in Italy. Eligible participants were adults (≥18 years) with newly diagnosed, histologically confirmed follicular lymphoma (stage I or II; grade I-IIIa). Patients were initially treated with 24 Gy involved-field radiotherapy over 12 days; those who were MRD-positive after radiotherapy or during follow-up received eight intravenous doses (1000 mg per dose; one dose per week) of the anti-CD20 mAb ofatumumab. The primary endpoint was the proportion of patients who were MRD-positive after involved-field radiotherapy and became MRD-negative after ofatumumab treatment. Patients were included in the primary endpoint analysis population if they were positive for BCL2::IGH rearrangement at enrolment in peripheral blood or bone marrow samples. MRD positivity was defined as the persistence of BCL2::IGH rearrangement in peripheral blood or bone marrow, assessed centrally by laboratories of the FIL MRD Network. The trial was registered with EudraCT, 2012-001676-11. FINDINGS: Between May 2, 2015, and June 1, 2018, we enrolled 110 participants, of whom 106 (96%) were eligible and received involved-field radiotherapy. Of these, 105 (99%) were White, one (1%) was Black, 50 (47%) were male, and 56 (53%) were female. Of 105 participants in whom BCL2::IGH status was evaluable, 32 (30%) had a detectable BCL2::IGH rearrangement at baseline. After radiotherapy, 12 (40%) of 30 patients reached MRD-negative status, which was long-lasting (at least 36 or 42 months) in three (25%). In those who were MRD-positive after radiotherapy, ofatumumab induced MRD-negativity in 23 (92%; 95% CI 74-99) of 25 evaluable patients. After a median follow-up of 46·1 months (IQR 42·8-50·8), 14 (61%) of these 23 patients remain in complete response and are MRD-negative. The most common grade 3-4 adverse events were infusion-related reactions, observed in four patients. INTERPRETATION: Local radiotherapy is frequently not associated with the eradication of follicular lymphoma. An MRD-driven, anti-CD20 monoclonal antibody consolidation enables molecular remission to be reached in almost all patients and is associated with a reduced incidence of relapse over time. A clinical advantage of an MRD-driven consolidation is therefore suggested. FUNDING: AIRC Foundation for Cancer Research in Italy, Novartis International, and GlaxoSmithKline.
引用
- Pulsoni A, Ferrero S, Tosti ME, et al. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. Lancet Haematol. 2024. PMID: 38937025. doi:10.1016/S2352-3026(24)00143-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。